Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer

Laura Muñoz-Moreno, Andrew V. Schally, Juan C. Prieto, M. José Carmena, Ana M. Bajo

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: Therapeutic strategies should be designed to transform aggressive prostate cancer phenotypes to a chronic situation. To evaluate the effects of the new growth hormone-releasing hormone receptor (GHRH-R) antagonists: MIA-602, MIA-606, and MIA-690 on processes associated with cancer progression as cell proliferation, adhesion, migration, and angiogenesis. Methods: We used three human prostate cell lines (RWPE-1, LNCaP, and PC3). We analyzed several molecules such as E-cadherin, β-catenin, Bcl2, Bax, p53, MMP2, MMP9, PCNA, and VEGF and signaling mechanisms that are involved on effects exerted by GHRH-R antagonists. Results: GHRH-R antagonists decreased cell viability and provoked a reduction in proliferation in LNCaP and PC3 cells. Moreover, GHRH-R antagonists caused a time-dependent increase of cell adhesion in all three cell lines and retarded the wound closure with the highest value with MIA-690 in PC3 cells. GHRH-R antagonists also provoked a large number of cells in SubG0 phase revealing an increase in apoptotic cells in PC3 cell line. Conclusions: Taken all together, GHRH-R antagonists of the MIAMI series appear to be inhibitors of tumor progression in prostate cancer and should be considered for use in future therapeutic strategies on this malignancy.

Original languageEnglish (US)
Pages (from-to)915-926
Number of pages12
JournalProstate
Volume78
Issue number12
DOIs
StatePublished - Sep 1 2018

Keywords

  • GHRH-R
  • angiogenesis
  • antagonists
  • cell adhesion
  • cell proliferation
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'Growth hormone-releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer'. Together they form a unique fingerprint.

Cite this